Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma
10.3904/kjm.2019.94.2.152
- Author:
Heejung CHAE
1
;
Dok Hyun YOON
Author Information
1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. dhyoon@amc.seoul.kr
- Publication Type:Review
- Keywords:
B-cell non-Hodgkin lymphoma;
Lymphoma, Large B-cell, Diffuse;
Chimeric antigen receptor T-cell;
CAR-T and immunotherapy
- MeSH:
B-Lymphocytes;
Biomarkers;
Cell- and Tissue-Based Therapy;
Humans;
Korea;
Lymphoma, B-Cell;
Lymphoma, Large B-Cell, Diffuse;
Organization and Administration;
Receptors, Antigen;
T-Lymphocytes;
United States Food and Drug Administration
- From:Korean Journal of Medicine
2019;94(2):152-158
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
CD19 chimeric antigen receptor T-cell (CAR-T) therapy, a genetically engineered cell therapy, showed unprecedented efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Two agents, axicabtagene ciloleucel and tisagenlecleucel, were approved by the Food and Drug Administration in 2017. However, CAR-T therapy is a treatment with complex logistics and high costs, as well as inherent adverse events, including cytokine-release syndrome and neurotoxicity. In addition, predictive biomarkers for efficacy and toxicity are lacking. Industry-academy cooperation is urgently required to develop CAR-T therapy that is effective, safe, and affordable for patients in Korea.
